PMID: 6402855Feb 1, 1983Paper

Assembly of the tail protein of the Bacillus subtilis phage phi 29

Virology
J A GarcíaM Salas

Abstract

By in vitro complementation we have determined that gene 13 product functions during phi 29 morphogenesis after the formation of 11- particles, specifically in the functional assembly of the tail protein, p9. Protein p9 from 8- but not from 8-13- extracts assembles in vitro into either 11-13- or 12-13- particles. The action of gene 13 product on p9 for its correct assembly has to take place in vivo; no complementation of 12-13- and 9- lysates occurs in vitro. Protein p9, isolated from phi 29-infected cells, copurifies with the 13+ activity and it is present both in 13+ and 13- extracts as an aggregate with dimensions similar to those of the tail assembled in mature phage.

References

May 17, 1976·European Journal of Biochemistry·R P MelladoM Salas
Jul 1, 1976·European Journal of Biochemistry·J L CarrascosaM Salas
Sep 1, 1971·Virology·E MéndezE Viñuela
Oct 1, 1972·Virology·M SalasE Viñuela
May 1, 1973·Journal of Bacteriology·J N ReeveR M Cole
Aug 30, 1974·FEBS Letters·J L CarrascosaM Salas
Apr 1, 1972·Virology·G RamírezE Viñuela
Jan 1, 1980·Molecular & General Genetics : MGG·J A García, M Salas
Jan 15, 1982·Journal of Molecular Biology·J L CarrascosaA Santisteban
Jul 15, 1982·Journal of Molecular Biology·J L CarrascosaM Salas

❮ Previous
Next ❯

Citations

Aug 14, 2012·Applied and Environmental Microbiology·Hans Petter KleppenSung-Sik Yoon
May 31, 2001·Microbiology and Molecular Biology Reviews : MMBR·W J MeijerM Salas
Jul 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ye XiangMichael G Rossmann
Apr 14, 2009·Journal of Molecular Biology·Daniel N CohenDavid L Popham
Oct 21, 2006·The EMBO Journal·Ye XiangMichael G Rossmann
Jun 1, 1984·Journal of Virology·M A BjornstiD L Anderson
Apr 9, 2008·Journal of Molecular Biology·Daniel N CohenDwight L Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.